CClinicalTrials.gg
Status unknownNCT00452049Updated May 30, 2012

The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure

An observational study in Hyperparathyroidism and Hypertension, sponsored by Universitaire Ziekenhuizen KU Leuven. Status unknown at 1 site in Belgium. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-05-30.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

The sponsor has not verified this record recently (last verified May 2012), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH.

Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function.

Aims:

  1. To evaluate the effect of parathyroidectomy (PTX) on renal hemodynamics in stable renal transplant recipients
  2. To evaluate the effect of PTX on endothelial function in stable renal transplant recipients/chronic kidney disease (CKD) stage 5 patients
  3. To evaluate the effect of PTX on blood pressure in stable renal transplant recipients/CKD stage 5 patients
02

Conditions studied

  • Hyperparathyroidism
  • Hypertension

Browse trials for

Keywords

  • parathyroidectomy
  • arterial stiffness
  • renal function
03

In context

Hyperparathyroidism

305 studies on the registry are indexed under Hyperparathyroidism; 23 are open to participants now.

This study's planned enrollment of 20 is below the median of 100 across 88 observational studies indexed under Hyperparathyroidism.

Browse Hyperparathyroidism studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Renal transplant recipients

Eligibility criteria

Inclusion Criteria:

  1. Stable renal transplant recipients/CKD stage 5D patients.
  2. Age between 18 years and 85 years.
  3. Signed informed consent.
  4. PTX scheduled because of severe hyperparathyroidism (day 0)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)

Interventions

  • Procedureparathyroidectomy

    parathyroidectomy

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D. Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. Transplantation. 2016 Oct;100(10):2188-93. doi: 10.1097/TP.0000000000001311. PubMed 27379556 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00452049
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Responsible party
Evenepoel Pieter (MD, PhD, Universitaire Ziekenhuizen KU Leuven) — Principal investigator
First posted
Mar 26, 2007
Start date
Apr 2005
Last update
May 30, 2012

Study contacts

Pieter Evenepoel, MD, PhD
Contact
pieter.evenepoel@uz.kuleuven.ac.be
003216344580
Pieter Evenepoel, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion